Obstetrics and Gynaecology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/208

Filters

2020 - 2023 2
1 1
Reset filters

Settings
Statistics
Citations
Author: Beard, Sally × Author: Nguyen, Tuong-Vi × Start date: 2020 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
    Binder, NKK ; Beard, S ; de Alwis, N ; Fato, BRR ; Nguyen, T-V ; Kaitu'u-Lino, TJ ; Hannan, NJJ (MDPI, 2023-04)
    Preeclampsia is associated with an increased lifelong risk of cardiovascular disease (CVD). It is not clear whether this is induced by persistent systemic organ and vascular damage following preeclampsia or due to a predisposition to both conditions that share cardiovascular pathophysiology. Common to both CVD and preeclampsia is the dysregulation of corin and its proteolytic product, atrial natriuretic peptide (ANP). ANP, a hypotensive hormone converted from pro-ANP by corin, is involved in blood pressure homeostasis. While corin is predominantly a cardiac enzyme, both corin and pro-ANP are significantly upregulated in the gravid uterus and dysregulated in preeclampsia. Relatively little is known about ANP function in the endothelium during a pregnancy complicated by preeclampsia. Here, we investigated the effect of ANP on endothelial cell proliferation and migration, markers of endothelial dysfunction, and receptor expression in omental arteries exposed to circulating preeclamptic toxins. ANP receptor expression is significantly upregulated in preeclamptic vasculature but not because of exposure to preeclampsia toxins tumour necrosis factor α or soluble fms-like tyrosine kinase-1. The supplementation of endothelial cells with ANP did not promote proliferation or migration, nor did ANP improve markers of endothelial dysfunction. The role of ANP in preeclampsia is unlikely to be via endothelial pathways.
  • Item
    No Preview Available
    The New Generation Antiplatelet Agent Prasugrel Represents an Exciting Novel Candidate Therapy for Preeclampsia.
    De Alwis, N ; Binder, N ; Beard, S ; Vi, N ; Tu'uhevaha, K-L ; Tong, S ; Hannan, N (SPRINGER HEIDELBERG, 2020-03)